Therakind acquires IP to novel dry powder nasal device, DriDose®
DriDose® to form basis of Therakind novel delivery platform
1st September 2020 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, today announces that it has signed an exclusive agreement with Indosys Limited to acquire the intellectual property for DriDose® an innovative dry powder nasal device.
Intranasal medicine delivery not only allows for accurate and consistent dose delivery, but achieves rapid, effective blood levels of the administered medication. DriDose® is a Dry Powder Intranasal Device for non-invasive and painless delivery of a dry powder drug formulation which is suitable for the delivery of small molecules, proteins, peptides and vaccines. Therakind’s products are specially designed to improve adherence, particularly in difficult-to-treat patient groups. DriDose® is easy to use with no specialist training or sterile technique required in a single-handed operation and can be used by the physician, care-giver or patient themselves, and provides multiple market opportunities. The device can be used on unconscious patients as no active inhaling technique is required and its dry powder formulation enables a long shelf life.
Susan Conroy, CEO of Therakind, said:
“DriDose® provides the basis of a novel delivery platform we are currently developing. It provides key aspects which match our mission to provide new medicines that will improve medicine adherence, particularly in difficult-to-treat patients groups including children, the elderly and those suffering with chronic diseases. We believe with the platform advancements we can bring, DriDose® will offer multiple licensing opportunities across the globe.”
For those interested in partnering DriDose® with Therakind, please contact us on bd@therakind.com
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Therakind Limited
Therakind is a specialty pharmaceutical company focused on developing niche products in difficult-to-treat markets including paediatric and geriatric patient groups. We have three paediatric products on the market, with Jylamvo, our European approved oral methotrexate for treating rheumatological and dermatological diseases expanded to treat adults, and DriDose®, our Dry Powder Intranasal Device for the delivery of a dry powder drug formulation available for partnering. Our proprietary pipeline is focused on improving medicine adherence through easier dosing regimens and we have a strong track record in the research and development of innovative medicines and drug delivery systems designed specifically to take into account the pharmacodynamics and pharmacokinetics of difficult-to-treat patient groups.
To find out more, please head to www.therakind.com
About Accord Healthcare
Headquartered in the United Kingdom (UK), Accord Healthcare Europe is one of the fastest growing pharmaceutical companies in Europe. Accord has one of the largest market footprints of any European generic and biosimilars companies selling generic medicines in over 80 countries around the world.
This global footprint enables us to deliver vital, affordable medicines to national health systems supporting healthcare professionals to transform patient lives worldwide.
Our approach is agile and inventive, always seeking to improve our products and patients’ access to them. We’re driven to think differently and deliver more for the benefit of patients worldwide.
